Synlogic (SYBX) Revenue & Revenue Breakdown
Synlogic Revenue Highlights
Latest Revenue (Y)
$3.37M
Latest Revenue (Q)
$8.00K
Synlogic Revenue by Period
Synlogic Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $3.37M | 185.68% |
2022-12-31 | $1.18M | -32.73% |
2021-12-31 | $1.75M | 221.83% |
2020-12-31 | $545.00K | -75.49% |
2019-12-31 | $2.22M | -11.75% |
2018-12-31 | $2.52M | 3.11% |
2017-12-31 | $2.44M | 100.00% |
2016-12-31 | - | 100.00% |
2015-12-31 | - | 100.00% |
2014-12-31 | - | 100.00% |
2013-12-31 | - | 100.00% |
2012-12-31 | - | - |
Synlogic Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-03-31 | $8.00K | -99.71% |
2023-12-31 | $2.77M | 604.58% |
2023-09-30 | $393.00K | 1022.86% |
2023-06-30 | $35.00K | -79.89% |
2023-03-31 | $174.00K | 64.15% |
2022-12-31 | $106.00K | -84.37% |
2022-09-30 | $678.00K | 346.05% |
2022-06-30 | $152.00K | -37.70% |
2022-03-31 | $244.00K | -58.78% |
2021-12-31 | $592.00K | -35.37% |
2021-09-30 | $916.00K | 272.36% |
2021-06-30 | $246.00K | 100.00% |
2021-03-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2020-09-30 | - | -100.00% |
2020-06-30 | $445.00K | 345.00% |
2020-03-31 | $100.00K | -91.87% |
2019-12-31 | $1.23M | 303.28% |
2019-09-30 | $305.00K | -12.86% |
2019-06-30 | $350.00K | 3.55% |
2019-03-31 | $338.00K | 204.50% |
2018-12-31 | $111.00K | -93.84% |
2018-09-30 | $1.80M | 609.06% |
2018-06-30 | $254.00K | -28.25% |
2018-03-31 | $354.00K | 218.92% |
2017-12-31 | $111.00K | - |
2017-09-30 | $111.00K | -94.74% |
2017-06-30 | $2.11M | 1801.80% |
2017-03-31 | $111.00K | - |
2016-12-31 | $111.00K | 100.00% |
2016-09-30 | - | 100.00% |
2016-06-30 | - | 100.00% |
2016-03-31 | - | 100.00% |
2015-12-31 | - | 100.00% |
2015-09-30 | - | 100.00% |
2015-06-30 | - | 100.00% |
2015-03-31 | - | 100.00% |
2014-12-31 | - | 100.00% |
2014-09-30 | - | - |
Synlogic Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
ACIU | AC Immune SA | $14.80M | - |
STOK | Stoke Therapeutics | $8.78M | $4.22M |
FRTX | Fresh Tracks Therapeutics | $8.01M | - |
KRON | Kronos Bio | $6.29M | $2.69M |
GBIO | Generation Bio | $5.90M | $4.06M |
SYBX | Synlogic | $3.37M | $8.00K |
SABS | SAB Biotherapeutics | $2.24M | $263.14K |
VCNX | Vaccinex | $570.00K | $232.00K |
CCCC | C4 Therapeutics | - | - |
ANTX | AN2 Therapeutics | - | - |
TARA | Protara Therapeutics | - | - |
GRTX | Galera Therapeutics | - | - |
ERAS | Erasca | - | - |
PCSA | Processa Pharmaceuticals | - | - |
PASG | Passage Bio | - | - |
MNPR | Monopar Therapeutics | - | - |
THRD | Third Harmonic Bio | - | - |
GLUE | Monte Rosa Therapeutics | - | $4.70M |
FDMT | 4D Molecular Therapeutics | - | - |
EWTX | Edgewise Therapeutics | - | - |
SRZN | Surrozen | - | - |
EFTR | eFFECTOR Therapeutics | - | - |
SYBX Revenue FAQ
What is Synlogic’s yearly revenue?
Synlogic's yearly revenue for 2023 was $3.37M, representing an increase of 185.68% compared to 2022. The company's yearly revenue for 2022 was $1.18M, representing a decrease of -32.73% compared to 2021. SYBX's yearly revenue for 2021 was $1.75M, representing an increase of 221.83% compared to 2020.
What is Synlogic’s quarterly revenue?
Synlogic's quarterly revenue for Q1 2024 was $8K, a -99.71% decrease from the previous quarter (Q4 2023), and a -95.40% decrease year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $2.77M, a 604.58% increase from the previous quarter (Q3 2023), and a 2512.26% increase year-over-year (Q4 2022). SYBX's quarterly revenue for Q3 2023 was $393K, a 1022.86% increase from the previous quarter (Q2 2023), and a -42.04% decrease year-over-year (Q3 2022).
What is Synlogic’s revenue growth rate?
Synlogic's revenue growth rate for the last 3 years (2021-2023) was 92.19%, and for the last 5 years (2019-2023) was 51.57%.